Study Summary. Results: All tested media-filled vials were negative for growth of any microorganisms.
|
|
- Kathlyn Maxwell
- 6 years ago
- Views:
Transcription
1 A 7 Days Microbial Ingress Test of Single Use Vials Utilizing the EQUASHIELD Closed System Drug Transfer Device Study by Nelson Laboratories (Salt Lake City, UT) 2013, updated in 2014* Study Summary Abstract: Aim: To perform an extreme-use-conditions test and assess the ability of the Equashield Closed System Transfer Device to prevent the microbial contamination of parenteral drug vials during 7 days of use. Method: Four groups of vials containing growth media were accessed with 770 Equashield syringes. Each vial was accessed 10, 7 and 5 times respectively during 7 days using the Equashield CSTD and 4ml were drawn off each time. Before each of the 770 accesses, the access membranes of Equashield Vial Adaptors were inoculated with (>10 3 CFU) with gram positive or gram negative bacteria respectively and were left to settle during ½ an hour on the membrane. Initially the Vial Adaptors were spiked onto the mediafilled vials two days earlier and incubated, resulting in a total of 9 days of testing, from first spiking to last access, and a total of 770 tested Equashield Syringes and vial accesses. The tested vials were incubated once again after the 9 days of testing and examined to demonstrate the ability of the Equashield CSTD to prevent vial contamination during 7 days of use. To further increase the challenge and the extreme use conditions, approximately a third of the tested Equashield devices were old expired products. Results: All tested media-filled vials were negative for growth of any microorganisms. Introduction: Equashield is a Closed System Transfer Device (CSTD) for the preparation and administration of hazardous drugs and it is cleared under FDA s product code ONB for closed antineoplastic and hazardous drug reconstitution and transfer systems. It complies with NIOSH s definition: A drug transfer device that mechanically prohibits the transfer of environmental contaminants into the system and the escape of hazardous drug or vapor concentrations outside the system 2. As a CSTD that is designated for working with hazardous drugs, the compliance of Equashield with especially the second part of NIOSH s definition 2 has been extensively tested in clinical and scientific studies and proven to be compliant, namely: mechanically prohibits the escape of hazardous drug or vapor concentrations outside the system. In order to achieve full closure of the Equashield CSTD and contamination free connections, unprecedented mechanisms and design features were incorporated into the CSTD, which in turn created a natural advantage for the CSTD over conventional systems and methods, whereby the risk of the transfer of microbial contaminants into the system is minimized. In another aspect, the United States Pharmacopeia (USP) Chapter 797 standards 1 mandate that single-use or non-preserved drugs must be discarded 6 hours after first vial access, if the vial is accessed and remains in ISO class 5 air conditions, otherwise it must be discarded after 1 hour. The purpose of this USP standard 1 is to provide patient protection by limiting the impact potential of any microbial contamination of the drug. On the other hand, it creates significant waste of partially used viable drugs, which in turn, increase financial expenditure. This includes the high-cost drugs which
2 are discarded in spite of the fact that the majority of them remain chemically stable for days and weeks. Published economical surveys demonstrate the obvious saving potential of the wasted drugs (in $Millions) if CSTDs can be proven capable of prohibiting the transfer of microbial contaminants into the drug vial to maximize the utilization of the drug. Furthermore, such savings can also finance the cost of the CSTDs. The Phaseal CSTD (Becton & Dickinson) has demonstrated the potential to prevent microbial ingress in vials up to 7 days in the following studies: Utility of the PhaSeal Closed System Drug Transfer Device, Derek M. McMichael et al., Am J Pharm Benefits. 2011;3(1): ; and Second Look at Utilization of a Closed-System Transfer Device (PhaSeal), E. Thomas Carey et al., Am J Pharm Benefits. 2011;3(6): Basically in these studies 3,4, vials containing growth media were accessed 5 times during 7 days and each time a transfer of a small portion from the vial content took place using the Phaseal CSTD under ISO 5 air conditions. Membrane disinfections and other standard aseptic techniques were used as well. The vials, simulating the drugs, were incubated after the 7 days of testing and examined to demonstrate the ability to prevent vial contamination during 7 days of use. Aim: The aim of the current study was to perform a significantly more extreme-use-conditions test than worse conditions expected in hospital pharmacy setting and worse than conditions of the above referenced previous studies 3,4, thus assessing the ability of the Equashield CSTD to prevent the contamination of parenteral drug products during 7 days of use. Method: The challenge procedure consisted of inoculating the access membrane surface of multiple test article replicates of the Equashield Vial Adaptor with gram positive or gram negative bacteria respectively, allowing the challenge to act and dry during ½ an hour, disinfecting the Vial Adaptor with a 70% isopropyl alcohol (IPA) pad, allowing the IPA to dry, connecting a new proprietary mating Equashield 20ml Syringe Unit to the Vial Adaptor, and drawing a 4ml aliquot of sterile media (Soybean Casein Digest Broth) from the 50ml media-filled vial that the adapter was installed on. The test protocol specified a minimum inoculation titer of 10 3 colony forming units (CFU) per adaptor inoculation. The vials were divided into three similar groups and tested while the fourth group was added and tested in a replicated test one year later according FDA s request. The first vial access was on day 1 at the commencement of the 9 day test, when the Vial Adaptors were spiked onto the sterile media-filled vials and then incubated two days long. Following their incubation and starting on day 3 the Vial Adaptors were each subjected to a total of 10 or 7 or 5 (group respectively) inoculation-disinfection-access-transfer cycles over 7 calendar days, more specifically on days 3,4,5,8 and 9. The adapters were accessed once or twice each day, resulting in a total of 770 tested Equashield Syringe Units with accesses and transfers. The first three groups were tested with Staphylococcus aureus (American type Culture Collection ATCC #6538) and group four was tested in addition to S. aureus with Staphylococcus epidermidis, Klebsiella pneumoniae, Pseudomonas Aeruginosa.
3 Pseudomonas Aeruginosa Klebsiella pneumoniae Staphylococcus aureus Staphylococcus epidermidis To maintain equivalence with clinical use in hospital pharmacy, ISO 5 air conditions were used in this study and only one person for each group performed the testing without assistance. Furthermore, approximately a third of the tested Equashield syringes and adapters were old products with expired use-dates. The tested vials were incubated for 2 days at C after the 9 days of testing and examined to demonstrate the ability of the Equashield CSTD to prevent vial contamination during 7 days of use. Results: All tested media-filled vials were negative for growth of any microorganisms. Discussion: The results of the study confirmed that despite the extreme-use clinical conditions, the Equashield CSTD prevented the microbial contamination of media-filled vials, which are more sensitive to contamination than drugs. The penetration of even one microorganism is sufficient to create full contamination, and although the chances of bacteria survival and growth inside a hazardous drug vial are very slim, the media-filled vials used in the current study provided ample conditions for their multiplication and spreading. To create even more extreme conditions, the vials in the current study were accessed up to 10 and 7 times during 7 days, whereas vials in previous studies 3,4 were accessed only 5 times. Since the ability of a single connector to prevent contamination is naturally decreased with every additional connection and access, therefore the number of connections gains increased significance in view of this non-linearly growing potential of contamination. The repeated inoculation of the membrane with vivid bacteria before each of the vial accesses poses an extreme challenge to this primary microbial barrier; a challenge that does not exist (to such an extent) in a hospital routine setting, and that was also not included in the referenced studies 3,4. Without the special mechanisms and design features incorporated into the Equashield connectors, the membrane alone would not be capable of such barrier performance. Actually, the doublemembrane connectors with their coring-free needles, special materials, and sequential guiding mechanisms, are responsible for creating the optimal conditions for satisfactory contamination prevention.
4 During the half hour that the bacteria were left to grow and settle on the membrane, the risk of them entering and settling in the openings or surface irregularities in the membrane, and subsequently moving into the vial or being moved by the penetrating needle, was obviously increased considerably in this study. In comparison, the FDA 5,7 requires a minimum of only 1 minute for challenging microbial barriers. The ½ hour challenging time was chosen since at longer challenging the bacteria dries and becomes inactive. The extreme conditions included the use of a significant number of Equashield syringes and adapters that were old products with expired use-dates, whereby the sterility of their packaging may have been compromised, as often occurs with old products, and therefore the risk of contamination was much greater than expected from new products that were more recently packaged. Unlike the conditions in many privileged hospital pharmacies and in previous studies 3,4, no cleanroom was used in this study and the laminar flow hood had an open front without the glass screen (which normally improves the isolation of the hood). To maintain equivalence with routine working procedures and conditions in a hospital pharmacy, only one person performed the testing without assistance, and the device packages were opened inside the hood. Furthermore, unlike experienced personnel in hospital pharmacies and previous studies 3,4, the operators were not proficient in using Equashield and only received basic training at the commencement of the study. The two types of vial accesses, namely: the spiking of the Vial Adaptor onto the vial and the access to the Vial Adaptor with the syringes, were purposely separated in this study. After spiking, the vials were incubated 2 days long and observed for turbidity before syringe accessing began. Both types of vial accesses were effective in preventing microbial ingress. Furthermore, larger needles are known to cause greater damage and increase leak potential to barrier membranes than thinner needles; therefore Equashield syringes with the larger needles were used in this study. Thus, it could be argued that the current study not only reaffirms previous studies results, it also indicates that the solution in the vials remained uncontaminated when using the Equashield CSTD in even more extreme conditions than may exist in hospital pharmacies, suggesting the possibility of practical benefit from the prevention of microbial ingress feature, especially for single-use or nonpreserved drugs. Conclusions: The current study unequivocally demonstrated that Equashield CSTD is capable of preventing the microbial ingress and contamination of drugs over 7 days of use, which makes it a true CSTD, compliant with both aspects of NIOSH s definitions 2, namely: mechanically prohibiting the transfer of environmental contaminants into the system and the escape of hazardous drug or vapor concentrations outside the system. Additionally, the standard disinfection procedure using IPA pads on Equashield access ports was identified as adequate in preventing microbial ingress. This ability of the CSTD, to provide extended microbial ingress prevention in extreme clinical conditions over a 7 day period, suggests improved patient protection in view of USP Chapter standards that currently limit the use of single-use non-preserved drugs to up to 6 hours in ISO class 5 air conditions. Disclaimer:
5 The purpose of this research is to demonstrate the potential use of the Equashield Closed System Device. Its publication does not constitute and must not be construed as promotion or advice to deviate from, alter or otherwise exceed the guidelines, rules and standard related to aseptic preparations and techniques, or in any way deviate, alter or exceed the USE DATE or SHELF LIFE of the drugs. For any modification a user must comply with required steps and measures to change the established guidelines, rules and standard related to aseptic preparations and techniques, such as the procedural changes described in USP 797. References: 1. United States Pharmacopeia. USP<797> Guidebook to Pharmaceutical Compounding Sterile Product Preparations. Rockville, MD: United States Pharmacopeial Convention. 2. National Institute for Occupational Safety and Health Alert - Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Healthcare Settings. DHHS (NIOSH) Publication No ; McMichael D M, Moore Jefferson D, Carey E T, Forrey R A, Spivey S. M., Mulvaney J, Jorgenson J A, Haughs R D - Utility of the PhaSeal Closed System Drug Transfer Device. Am J Pharm Benefits. 2011;3(1): Carey E T, Forrey RA, Haughs D, Moore Jefferson D, Jorgenson J A, McMichael D M, Mulvaney J M, Spivey S M - Second Look at Utilization of a Closed-System Transfer Device (PhaSeal). Am J Pharm Benefits.2011;3(6): Code of Federal Regulations Subpart D - Microbiological Assay Methods, Test Organisms. 21 CFR Ch. I ( Ed.). 6. United States Pharmacopeia 35 & National Formulary <797> Pharmaceutical Compounding-Sterile Preparations. United States Pharmacopeial Convention, Inc., Rockville, MD. 7. U.S. Department of Health and Human Services / Food and Drug Administration - Intravascular Administration Sets Premarket Notification Submissions [510(k)]. July, Study reports on file: 1. Group 1 test report # April 05, / 10 connections and accesses. 2. Group 2 test report # April 05, / 7 connections and accesses. 3. Group 3 test report # May 07, / connections and accesses. 4. Group 4 test report # April 04, / 5 connections and accesses. *Note: The testing of group 4 has been performed by Milouda & Migal Laboratories.
ChemoLock Needlefree Closed System Transfer Device
ChemoLock Needlefree Closed System Transfer Device Clinical Evidence Table of Contents Pg Number Studies Evaluating Environmental Contamination ph Liquid Integrity Test of FDA-Approved ONB Closed-System
More informationGuidance. Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography (PET) Drugs DRAFT GUIDANCE
Guidance Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography (PET) Drugs DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and
More informationGrowth Promotion Test Guide for Media Used in Sterility Tests
Growth Promotion Test Guide for Media Used in Sterility Tests The Sterility Test The purpose of the Sterility Test is to determine if a sample of a pharmaceutical product or component is sterile. A satisfactory
More informationHardyVal TM CSP RANDOM TEST KIT
HardyVal TM CSP RANDOM TEST KIT Cat. no. HVR1 Random Test Kit 5 tests/kit INTENDED USE Each kit contains: Tryptic Soy Broth, Double Strength (DS), 12ml Syringe, 5.2ml Whirl-Pak Bag Results Log Sheet 5
More informationHot Topics in Drug Product Process Validation: A Reviewer s Perspective
Hot Topics in Drug Product Process Validation: A Reviewer s Perspective Colleen Thomas, Ph.D. Quality Assessment Lead (Acting) FDA/CDER/OPQ/OPF Division of Microbiology Assessment CASSS CMC Strategy Forum
More informationHardyVal TM CSP MEDIUM-RISK LEVEL MEDIA-FILL CHALLENGE KITS
HardyVal TM CSP MEDIUM-RISK LEVEL MEDIA-FILL CHALLENGE KITS Cat. no. HVM1 Medium-Risk Level Media-Fill Comprehensive Challenge Test Kit - Bag Each kit contains: Tryptic Soy Broth (TSB), 1000ml Dual Port
More informationIn-Use Stability of Biological Parenteral Products:
In-Use Stability of Biological Parenteral Products: Aspects of physicochemical and microbiological stability after container penetration, reconstitution, dilution and hold time University Medical Center,
More informationAnnex A2. Guidance on Process Validation Scheme for Aseptically Processed Products
Annex A2 Guidance on Process Validation Scheme for Aseptically Processed Products 1 Table of content 1 PURPOSE... 3 2 SCOPE... 3 3 GENERAL INFORMATION... 3 4 INFORMATION NEEDED FOR ASEPTIC PROCESSES VALIDATION...
More informationWhy Do I Test, What Do I Test & When Do I Test It? Ross Caputo, PhD Chief Technical Officer Eagle Analytical Services
Why Do I Test, What Do I Test & When Do I Test It? Ross Caputo, PhD Chief Technical Officer Eagle Analytical Services Disclosures I, Ross Caputo, declare no conflicts of interest, real or apparent, and
More informationImmobilization and Death of Bacteria by Flora Seal Microbial Sealant
International Journal of Pharmaceutical Science Invention ISSN (Online): 2319 6718, ISSN (Print): 2319 670X Volume 6 Issue 6 June 2017 PP. 45-49 Immobilization and Death of Bacteria by Flora Seal Microbial
More informationFOCUS ON: Oncology Systems
FOCUS ON: Oncology Systems Delivering Excellence Focused and committed In to Oconology helping you Infusion deliver Therapy From Preparation To Administration Excellence in Powerful medications used in
More informationThis compilation of the complex
Manufacturing in a Global Marketplace Reference Matrices on Regulations for Classified (Environmentally Controlled) Areas Betty Seawell, William Miele, and Jean Huxsoll The complex world of international
More informationCompounding Pharmacies and the USP <71> Sterility Tests
Compounding Pharmacies and the USP Sterility Tests Scott Sutton, Ph.D. scott.sutton@microbiol.org 49 41 Disclaimer I am making this presentation as an independent agent I am not making this presentation
More informationBIO & PHARMA ANALYTICAL TECHNIQUES
BIO & PHARMA ANALYTICAL TECHNIQUES Chapter 11 by Dr. Siti Umairah Mokhtar Faculty of Engineering Technology umairah@ump.edu.my Chapter Description Aims Discuss theory, principles and application of analytical
More informationMethod Suitability Report Membrane Filtration Sterility Test with QTMicro Apparatus
Method Suitability Report Membrane Filtration Sterility Test with QTMicro Apparatus Bevacizumab (Avastin) 1.25 mg/0.05ml This report provides details on the specifics of a Membrane Filtration Sterility
More informationPharmacy Compounding: Infection Prevention
Pharmacy Compounding: Infection Prevention Sam Eberwein, PharmD, MS, BCPS Clinical Manager, Sterile Products Area, Perioperative Services, & Special Formulations UNC Medical Center Department of Pharmacy
More informationMicrobiological Quality of Drug Products after Penetration of the Container System for Dose Preparation Prior to Patient Administration
Microbiological Quality of Drug Products after Penetration of the Container System for Dose Preparation Prior to Patient Administration John W. Metcalfe, Ph.D. Senior Review Microbiologist FDA/CDER/OPS/New
More informationUSP Chapter 823 USP 32 (old) vs. USP 35 (new)
USP Chapter 823 USP 32 (old) vs. USP 35 (new) Sally W. Schwarz, MS, BCNP Research Associate Professor of Radiology Washington University School of Medicine St. Louis, MO Why USP Chapter ? FDA has
More informationGuidance for Industry
Guidance for Industry for the Submission Documentation for Sterilization Process Validation in Applications for Human and Veterinary Drug Products Center for Drug Evaluation and Research (CDER) Center
More informationOverview of a sterility assurance program for PET drugs
Coalition for PET Drug Approval Radiopharmaceutical Sciences Council Overview of a sterility assurance program for PET drugs Eric Webster, PETNET Solutions Disclosures Employee of PETNET Solutions, a Siemens
More informationSterile Compounding elearning Course Curriculum 28 lessons with 33 hours of CE. Fundamentals of Sterile Compounding (8 lessons/8 hours CE)
Sterile Compounding elearning Course Curriculum 28 lessons with 33 hours of CE Fundamentals of Sterile Compounding (8 lessons/8 hours CE) The History of Compounding and USP Sterile Compounding Chapters
More informationTests to Support Sterility Claim. Imtiaz Ahmed
Tests to Support Sterility Claim Imtiaz Ahmed Sterile Product As per TGO 77, a sterile product must comply with the requirements of the following tests: Sterility Test Bacterial Endotoxins Test Appendix
More informationThe ABCs and Challenges of GMP The American Experience
The ABCs and Challenges of GMP The American Experience The Canadian Association of Nuclear Medicine Toronto, Ontario April 22, 2017 Reiko Oyama, R.Ph., B.C.N.P. Washington University School of Medicine
More informationUSP Chapter <797> & <800> Testing Supplies
How clean are your testing supplies? USP Chapter & Testing Supplies The first aseptic products built to minimize risk starting with the packaging itself Smarter, Cleaner, Convenient Cultivate
More informationInfection and Intravenous Drug Delivery: A Long and Tumultuous Relationship
Infection and Intravenous Drug Delivery: A Long and Tumultuous Relationship Eric Wenzler, PharmD, BCPS, AAHVIP Assistant Professor University of Illinois at Chicago Disclosures I have no actual or potential
More informationSterile Compounding elearning Course Curriculum 28 lessons with 33 hours of CE. Fundamentals of Sterile Compounding (8 lessons/8 hours CE)
Sterile Compounding elearning Course Curriculum 28 lessons with 33 hours of CE CriticalPoint s Sterile Compounding elearning curriculum is written by industry experts and covers both Chapter and
More informationANNEX 1: COMMENT SUBMISSION DOCUMENT
Submission Comments on: GMP Annex 1: Proposal for amendments to the environmental classification table for particles and associated text, amendment to section 42 concerning acceptance criteria for media
More informationCompounding Aseptic Isolators (CAI) James T Wagner
Compounding Aseptic Isolators (CAI) James T Wagner jimwagner@cenvironment.com Disclaimer "Although I am a member of the USP Sterile Compounding Expert Committee, I am speaking today in my individual capacity
More informationIN THIS SECTION MICROBIOLOGY TESTING EXPERT SOLUTIONS FOR PRODUCT DEVELOPMENT. Bacterial Endotoxin (LAL) Testing
EXPERT SOLUTIONS FOR PRODUCT DEVELOPMENT IN THIS SECTION MICROBIOLOGY TESTING Microbial assays involve a variety of tests, from the determination of the numbers and types of organisms naturally present
More informationMicrobiology Testing: USP requirements for Sterile and Nonsterile Preparations Webinar Q&A
USP Antimicrobial Effectiveness Testing Microbiology Testing: Webinar Q&A 1. If a base ingredient is designed for the purpose of compounding a specific type of preparation does this forgo the necessity
More informationNew York State Department of Health - Wadsworth Center Laboratory of Environmental Biology NYS ELAP Laboratory ID 10765
New York State Department of Health - Wadsworth Center Laboratory of Environmental Biology NYS ELAP Laboratory ID 10765 Division of Environmental Health Sciences Albany, New York NYS DOH LEB-606 Identification
More informationToday s Topics. General Quality Control Best Practices. Practices Antimicrobial Effectiveness Testing(AET) Best Practices Environmental Isolates
Laboratory Best Practices in QC Microbiology Today s Topics General Quality Control Best Practices Growth Promotion Testing (GPT) Best Practices Antimicrobial Effectiveness Testing(AET) Best Practices
More informationSeptember 2, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852
September 2, 2014 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: FDA Draft Guidance: Current Good Manufacturing Practice Interim
More informationBaxa Corporation. Technical Paper. Environmental Controls for Sterile Compounding
Baxa Corporation Environmental Controls for Sterile Compounding Technical Paper A guidance document on developing sterile preparation areas to meet the USP requirements for low and medium risk compounded
More informationCleaning validation of cleanrooms and preparation equipments
Cleaning validation of cleanrooms and preparation equipments Dr Farshid SADEGHIPOUR Head of production Central Pharmacy, Geneva University Hospitals EAHP Foundation Seminar: Patient Safety; More About
More informationNew York State Department of Health - Wadsworth Center Laboratory of Environmental Biology NYS ELAP Laboratory ID 10765
New York State Department of Health - Wadsworth Center Laboratory of Environmental Biology NYS ELAP Laboratory ID 10765 Division of Environmental Health Sciences Albany, New York NYS DOH LEB-610 Identification
More informationLUNCH AND LEARN. October 14, CE Activity Information & Accreditation
LUNCH AND LEARN USP Chapter : What s on the Radar? October 14, 2016 Featured Speaker: Patricia C. Kienle, RPh, MPA, FASHP Director, Accreditation and Medication Safety Cardinal Health Innovative Delivery
More informationQUALITY ASSURANCE & AUDIT
QUALITY ASSURANCE & AUDIT Birinder Kaur Senior Pharmacist Pharmacy Dept National University Of Malaysia Medical Centre Kuala Lumpur birin@ppukm.ukm.edu.my LEARNING OBJECTIVES To define quality assurance
More informationDisinfection Qualification Testing
Disinfection Qualification Testing Considerations for Aseptic & Cleanroom Manufacturing Environments White Paper Considerations for Aseptic and Cleanroom Manufacturing Environments Obtaining the highest
More informationNEIlON LABORATORY FINAL REPORT TIME KILL STUDY PROCEDURE NO. STP0158 REV 01 PROTOCOL DETAIL SHEET NO REV 01
NEIlON FINAL REPORT TIME KILL STUDY PROCEDURE NO. STP0158 REV 01 PROTOCOL DETAIL SHEET NO. 200901442 REV 01 LABORATORY NO. 474527A PREPARED FOR: KEITH MOELLER AMERICAN BIOTECH LABS 80 W. CANYON CREST RD.
More informationEndoscope Microbial Surveillance Testing Made Easy
Endoscope Microbial Surveillance Testing Made Easy Alpa Patel, B.S.RM (NRCM) Senior Scientist Nelson Laboratories Kaumudi Kulkarni, M.S. Manager of Research and Development Healthmark Industries Disclosure
More informationFDA s Guidance for Industry
Sterile Drug Products Produced by Aseptic Processing - CGMPs Midwest FDC Conference November 4 2005 Susan Bruederle, Investigator FDA / ORA / Central Region Chicago District / Hinsdale IL FDA s Guidance
More informationThe expanding complexity of
A Vaccine Case Study Qualifying Redundant Disconnection Technologies As Container-Closure Systems for Long-Term Storage and Shipping Christine Megarity and Bobbi Allen The expanding complexity of biopharmaceutical
More informationMicrobiological Challenge Test of Contamination Caused by Using the PhaSeal System
Regular Article Jpn. J. Pharm. Health Care Sci. 39(3) 148 155 (2013) Microbiological Challenge Test of Contamination Caused by Using the PhaSeal System Koji Hama *1, Tohru Hashida 1 and Kazusaburo Kataoka
More informationIndustry Perspective on PET Manufacturing Comparison of EU and US
Standards for Imaging Endpoints and Manufacturing of PET Radiopharmaceuticals Industry Perspective on PET Manufacturing Comparison of EU and US Guidances and associated Regulations Natcher Conference Center
More information3.2 Test for sterility
This text is based on the internationally-harmonized texts developed by the Pharmacopoeial Discussion Group (PDG). Some editorial modifications have been made in order to be in line with the style used
More informationDrug Products, Labeling, and Packaging
442 Pharmaceutical Industry: Drug Products, Labeling, and Packaging Positions Drug Products, Labeling, and Packaging Ready-to-Administer Packaging for Hazardous Drug Products Intended for Home Use (1711)
More informationNew York State Department of Health - Wadsworth Center Laboratory of Environmental Biology NYS ELAP Laboratory ID 10765
New York State Department of Health - Wadsworth Center Laboratory of Environmental Biology NYS ELAP Laboratory ID 10765 Division of Environmental Health Sciences Albany, New York NYS DOH LEB-608 Identification
More informationCase study Microbiological excursion during a phase I PQ of a WFI system. Walid El Azab Technical Service Manager STERIS Life Science
Case study Microbiological excursion during a phase I PQ of a WFI system Walid El Azab Technical Service Manager STERIS Life Science Agenda Agenda Case study Microbiological excursion Description of the
More informationUNDER SECRETARY FOR HEALTH S INFORMATION LETTER MICROBIOLOGICAL ASSESSMENT OF PHARMACEUTICAL CLEANROOMS
DEPARTMENT OF VETERANS AFFAIRS Veterans Health Administration Washington DC 20420 IL 10-2006-008 In Reply Refer To: 10NB UNDER SECRETARY FOR HEALTH S INFORMATION LETTER MICROBIOLOGICAL ASSESSMENT OF PHARMACEUTICAL
More informationPosition: Sr. Director of Education and Data - NHIA, VP of Research - NHIF
Comment Submission Template for: General Chapter Pharmaceutical Compounding Sterile Preparations Revision proposed in Pharmacopeial Forum 41(6) Nov/Dec 2015 Send completed template to CompoundingSL@usp.org
More informationTECHNICAL LEAFLET. MEDI-MEDIA-FILL KIT SUPPLY PACKAGE (Code: MR-25/S)
TECHNICAL LEAFLET MEDI-MEDIA-FILL KIT SUPPLY PACKAGE (Code: MR-25/S) TEST AGAR PLATES FOR PERSONNEL AND ENVIRONMENTAL MICROBIOLOGICAL MONITORING COMPONENTS: Test Agar Plates Data Log Sheet Technical Leaflet
More informationPHARMACY IV ADMIXTURE
PHARMACY IV ADMIXTURE Pharmacy 483 January 18, 2007 Kim Donnelly Affiliate Assistant Professor kimdon@u.washington.edu Pharmacist is responsible for ensuring that compounded sterile preparations are properly
More informationGUIDE TO INSPECTIONS OF MICROBIOLOGICAL PHARMACEUTICAL QUALITY CONTROL LABORATORIES
GUIDE TO INSPECTIONS OF MICROBIOLOGICAL PHARMACEUTICAL QUALITY CONTROL LABORATORIES Note: This document is reference material for investigators and other FDA personnel. The document does not bind FDA,
More informationICH Topic Q4B Annex 8 Sterility Test General Chapter. Step 3
European Medicines Agency December 2008 EMEA/CHMP/ICH/645592/2008 ICH Topic Q4B Annex 8 Sterility Test General Chapter Step 3 ANNEX 6 TO NOTE FOR EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL TEXTS FOR
More informationNew York State Department of Health - Wadsworth Center Laboratory of Environmental Biology NYS ELAP Laboratory ID 10765
New York State Department of Health - Wadsworth Center Laboratory of Environmental Biology NYS ELAP Laboratory ID 10765 Division of Environmental Health Sciences Albany, New York NYS DOH LEB-606 Identification
More informationRe: Insanitary Conditions at Compounding Facilities, Guidance for Industry (Docket ID: FDA-2016-D )
Division of Dockets Management (HFA-305) Food and Drug Administration Department of Health and Human Services 5630 Fishers Lane, Room 1061 Rockville, MD 20852 [Submitted electronically to www.regulations.gov]
More informationSolutions for All Your Aseptic Parenteral Drug Formulation/Filling Needs. BUBBLE-FREE FILLING : A New Option in Prefilled Syringe Filling
WHITEPAPER Hyaluron Contract Manufacturing Solutions for All Your Aseptic Parenteral Drug Formulation/Filling Needs BUBBLE-FREE FILLING : A New Option in Prefilled Syringe Filling Introduction The advent
More informationDUAL SPECIES BIOLOGICAL INDICATOR SPORE STRIPS For Monitoring Ethylene Oxide (EO), Steam and Chemiclave Processes
DUAL SPECIES BIOLOGICAL INDICATOR SPORE STRIPS For Monitoring Ethylene Oxide (EO), Steam and Chemiclave Processes Reorder Code: STNS-65R Product Description Dual Species Biological Indicator Spore Strips
More informationThe Microbiological Requirements of a Stability Study. Ngoc Anh-Thu Phan 19 th June 2012
The Microbiological Requirements of a Stability Study Ngoc Anh-Thu Phan 19 th June 2012 Contents Introduction Harmonized Tests Acceptance Criteria Selection of Tests Why PE Testing? Selection of Category
More informationá61ñ MICROBIOLOGICAL EXAMINATION OF NONSTERILE PRODUCTS: MICROBIAL ENUMERATION TESTS
USP 40 Microbiological Tests / á61ñ Microbiological Examination 1 á61ñ MICROBIOLOGICAL EXAMINATION OF NONSTERILE PRODUCTS: MICROBIAL ENUMERATION TESTS INTRODUCTION The tests described hereafter will allow
More informationMicrobiology Research Associates
2017 Microbiology Research Associates List of Services www.mra-bact.com 33 Nagog Park Acton, MA 01720 978.263.2624 Page 1 of 11 Microbiology Tests Pharma/Biotech/Medical Devices Time From Sample Receipt
More information4.5 Compounding Compounding in Licensed Pharmacies.
0 0 0. Compounding. Compounding in Licensed Pharmacies. (a) Compounding means any of the following activities occurring in a licensed pharmacy, by or under the supervision of a licensed pharmacist, pursuant
More informationINSPECTOR S OBSERVATIONS AND WARNING LETTER
Microrite, Inc. San Jose, CA, USA, http://www.microrite.com AIR VELOCITY MEASUREMENTS AND CORRELATION TO SMOKE STUDIES FOR ASEPTIC OPERATIONS KEYWORDS Air Velocity, Air Flows, Smoke Study, Air Pattern
More informationRecent USP Updates May, 2013
Recent USP Updates May, 2013 Don Singer GSK Bioburden Control of Non-sterile Drug Substances and Products The chapter emphasizes control as a risk mitigation strategy The chapter recommends a risk-based
More informationPHARMACY IV ADMIXTURE. Pharmacy 483 January 17, 2006 Kim Donnelly Affiliate Associate Professor
PHARMACY IV ADMIXTURE Pharmacy 483 January 17, 2006 Kim Donnelly Affiliate Associate Professor Pharmacist is responsible for ensuring that compounded sterile preparations are properly prepared, labeled,
More informationNew York State Department of Health - Wadsworth Center Laboratory of Environmental Biology NYS ELAP Laboratory ID 10765
New York State Department of Health - Wadsworth Center Laboratory of Environmental Biology NYS ELAP Laboratory ID 10765 Division of Environmental Health Sciences Albany, New York NYS DOH LEB-612 Identification
More informationCGMP Requirements for Investigational Products
PREP #6 CGMP Requirements for Investigational Products Ji-Eun Kim, RPh, PhD Research Pharmacist Regulatory Affairs Office of Research Compliance December 6, 2016 1 CME Disclosure Statement Northwell Health
More informationBiological contamination events in isolators: What lessons can be learned?
WHITE PAPER SCIENCE DRIVEN BIO-DECONTAMINATION LS001-MKT-008 Rev 1US Biological contamination events in isolators: What lessons can be learned? James Drinkwater, Bioquell UK Process & Compliance Director.
More informationEnvironmental Monitoring of Aseptic Processing Areas - 2
Environmental Monitoring of Aseptic Processing Areas - 2 A war against an invisible enemy DCVMN - Víctor Maqueda - May 30, 31, June 1 2016 1 Active Air Monitoring (Viables) Air Sieve Samplers Draw air
More informationFINAL REPORT LOW LEVEL DISINFECTION EVALUATION VIOGUARD KEYBOARD
Test Report: Keyboard disinfection Page 1/31 FINAL REPORT LOW LEVEL DISINFECTION EVALUATION VIOGUARD KEYBOARD Subject: Microbial disinfection test, VIOGUARD, Inc keyboard Klebsiella pneumoniae Document
More informationINSTRUCTIONS FOR USE. EZ-CFU Microorganisms INTENDED USE FORMULA COMPONENTS
INSTRUCTIONS FOR USE EZ-CFU Microorganisms INTENDED USE EZ-CFU microorganisms are lyophilized, enumerated microorganism preparations to be used in industrial laboratories for quality control purposes.
More informationSoleris system evaluation of testing applications for UHT/aseptic packs
Summary system evaluation of testing applications for UHT/aseptic packs September 2012 Neogen Corporation (Lansing, Mich.) conducted internal studies to validate optimal test procedures for the ultrahigh
More informationUSP800: A quick summary and disposal. Brenda Denson, Pharm.D.
USP800: A quick summary and disposal Brenda Denson, Pharm.D. Objectives Review current USP800 guidelines on destruction of hazardous medications. Illustrate how a local pharmacy demonstrates compliance
More informationAMENDED Draft Report of the Compounding Workgroup
AMENDED Draft Report of the Compounding Workgroup This report summarizes the actions taken by a workgroup convened by the Board of Pharmacy pursuant to the enactment clause of HB 1035 passed during the
More informationDISINFECTION QUALIFI CATION TESTING CONSIDERATIONS FOR THE ASEPTIC AND CLEANROOM MANUFACTURING ENVIRONMENT
DISINFECTION QUALIFI CATION TESTING CONSIDERATIONS FOR THE ASEPTIC AND CLEANROOM MANUFACTURING ENVIRONMENT by Dave Rottjakob, M.T. (ASCP) December, 2013 INTRODUCTION Obtaining the highest confidence that
More informationá62ñ MICROBIOLOGICAL EXAMINATION OF NONSTERILE PRODUCTS: TESTS FOR SPECIFIED MICROORGANISMS
USP 40 Microbiological Tests / á62ñ Microbiological Examination 1 á62ñ MICROBIOLOGICAL EXAMINATION OF NONSTERILE PRODUCTS: TESTS FOR SPECIFIED MICROORGANISMS INTRODUCTION The tests described hereafter
More informationChemoLock. Setting a Whole New Standard for Hazardous Drug Safety. Don t you love it when everything just clicks? Introducing
Introducing ChemoLock Needlefree Closed System Transfer Device The first and only needlefree CSTD to receive FDA 510(k) clearance for both pharmacy (ONB) and patient administration (FPA) applications.
More informationNew York State Department of Health - Wadsworth Center Laboratory of Environmental Biology NYS ELAP Laboratory ID 10765
New York State Department of Health - Wadsworth Center Laboratory of Environmental Biology NYS ELAP Laboratory ID 10765 Division of Environmental Health Sciences Albany, New York NYS DOH LEB-603 Preparation
More informationINSTRUCTIONS FOR USE. EZ-CFU One Step Microorganisms INTENDED USE FORMULA COMPONENTS
INSTRUCTIONS FOR USE EZ-CFU One Step Microorganisms INTENDED USE EZ-CFU One Step microorganisms are lyophilized, enumerated microorganism preparations to be used in industrial laboratories for quality
More informationEvaluation of a Novel Non-Sterile Glove Dispensing System Uyen Nguyen
Evaluation of a Novel Non-Sterile Glove Dispensing System Uyen Nguyen Edited by: Michael Diamond Reviewed by: Andrew Duong Disclaimer: The author of this report and declare no conflict of interest with
More informationUS Regulatory Requirements: Clinical & Clinical Research Production, SPECT & PET Radiopharmaceuticals (RPs)
US Regulatory Requirements: Clinical & Clinical Research Production, SPECT & PET Radiopharmaceuticals (RPs) 20 th International Symposium Radiopharmaceutical Sciences Jeju, Korea Pre-Symposium Workshop
More informationBiocidal Surface Test - Clinell Wipes ~ Project Report Prepared for GAMA Healthcare Ltd ~ Huddersfield Microbiology Services Oct 06
Biocidal Surface Test - Clinell Wipes ~ Project Report Prepared for GAMA Healthcare Ltd ~ Huddersfield Microbiology Services Oct 06 Summary The ability of Clinell wipes to disinfect contaminated steel
More informationFOCUS ON: Oncology Systems
FOCUS ON: Oncology Systems Focused and committed to helping you deliver Enhance Patient Safety Excellence in Oncology IV Therapy Improve Clinical Efficiency Powerful medications used in cancer treatments
More informationNew York State Department of Health - Wadsworth Center Laboratory of Environmental Biology NYS ELAP Laboratory ID 10765
New York State Department of Health - Wadsworth Center Laboratory of Environmental Biology NYS ELAP Laboratory ID 10765 Division of Environmental Health Sciences Albany, New York NYS DOH LEB-607 Identification
More informationfor IND and RDRC Regulated PET Compounding
Overview of USP Chapter for IND and RDRC Regulated PET Compounding Distributed Manufacturing of PET Radiopharmaceuticals for Multi-Center Clinical Trials SNM, Annual Meeting Toronto, Ontario, Canada
More informationAseptic Process Validation
Aseptic Process Validation IMB GMP Information Seminar 27 th September 2012 Gerard Sheridan, Inspector Date Insert on Master Slide Slide 1 Overview Guidance Best Practices Common Deficiencies Slide 2 Aseptic
More informationThe Parenteral Drug Association
C O N F E R E N C E R E P O R T Equipment Cleaning Microbial Control Issues By Destin A. LeBlanc, M.A. Cleaning Validation Technologies Validation: The Parenteral Drug Association (PDA) spring conference
More informationMICROBIOLOGICAL CULTURE MEDIA
MICROBIOLOGICAL CULTURE MEDIA A COMPLETE GUIDE FOR PHARMACEUTICAL AND HEALTHCARE MANUFACTURERS Tim Sandle Microbiological Culture Media: A Complete Guide for Pharmaceutical and Healthcare Manufacturers
More informationPublic Health England (PHE) Certified Reference Materials for Microbiology. Certificate of Analysis
Public Health England (PHE) Certified Reference Materials for Microbiology Certificate of Analysis This certificate should not be parted from the PHE certified reference material with batch number: 1070-14
More informationIntroduction. Michael J. Miller, Ph.D. RMM»
RMM» Case Study of a New Growth-based Rapid Microbiological Method (RMM) that Detects the Presence of Specific Organisms and Provides an Estimation of Viable Cell Count Michael J. Miller, Ph.D. President
More informationReview Validation of aseptic processes for pharmaceuticals
OPEM www.opem.org Oriental Pharmacy and Experimental Medicine 2010 10(4), 231-238 DOI 10.3742/OPEM.2010.10.4.231 Review Validation of aseptic processes for pharmaceuticals Lincy Joseph*, Mathew George
More informationOverview of Inspection Issues with Legacy Products
Overview of Inspection Issues with Legacy Products Presented by Simone E. Pitts Consumer Safety Officer, USFDA Team Biologics simone.pitts@fda.hhs.gov Objective To provide some examples of recent inspectional
More informationEmcure Pharmaceuticals Limited 3/3/16
1 of 7 05/06/2016 8:22 AM U.S. Food and Drug Administration Protecting and Promoting Your Health Emcure Pharmaceuticals Limited 3/3/16 Department of Health and Human Services Public Health Service Food
More informationImproving the Safety of Compounded Preparations - USP <800> Compliance in Every Day Practice
Improving the Safety of Compounded Preparations - USP Compliance in Every Day Practice PSSNY Annual Convention, Westchester Hilton, Rye Brook, NY Sunday, June 25th at 9:00 AM Lou Diorio, RPh, FAPhA
More informationComplaints Investigations Root Cause Analysis
Complaints Investigations Root Cause Analysis Dr. Ademola Daramola International Relations Specialist Drugs US FDA India Office New Delhi February 22nd 2018 Information presented in this presentation does
More informationIQCP for Disk Diffusion Antimicrobial Susceptibility Testing (AST)
IQCP for Disk Diffusion Antimicrobial Susceptibility Testing (AST) Test System: Disk Diffusion Antimicrobial Susceptibility Testing (Kirby Bauer) / Twelve Disk Diffusion Test using BBL Disks Facility:
More informationMicrobiology for Oral and Topical Products - The basics Scott Colbourne Business Manager NSW ALS Food & Pharmaceutical
Microbiology for Oral and Topical Products - The basics Scott Colbourne Business Manager NSW ALS Food & Pharmaceutical RIGHT S O L U T I O N S RIGHT PARTNER Contents TGO 77 - Introduction Tests Performed
More informationEC-type approval protocol No. 2 Microbiological safety of toys containing aqueous media REV 2
Co-ordination of the Notified Bodies NB-TOYS under the Safety of Toys Directive NB- TOYS/2014/071 10 June 2014 EC-type approval protocol No. 2 Microbiological safety of toys containing aqueous media REV
More informationImportant Updates in USP <797> and USP <823> Eric S. Kastango, MBA, BS Pharm, FASHP Clinical IQ, LLC & CriticalPoint, LLC Madison, New Jersey
Important Updates in USP and USP Eric S. Kastango, MBA, BS Pharm, FASHP Clinical IQ, LLC & CriticalPoint, LLC Madison, New Jersey Disclosures Principal-Clinical IQ, LLC Healthcare consulting
More information